Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Frequently asked questions
What sector does Serina Therapeutics Inc (SER) operate in?
Serina Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Serina Therapeutics Inc (SER) current stock price?
As of the latest data, Serina Therapeutics Inc stock price is $1.71, with a previous close of $1.65. Serina Therapeutics Inc gained $0.06 in the last trading session, representing a 3.64% increase.
What is Serina Therapeutics Inc (SER) current market capitalization?
Serina Therapeutics Inc market cap is approximately 43.43 million.
What is Serina Therapeutics Inc (SER) Earnings Per Share (EPS)?
The trailing EPS is -$1.87, and the forward EPS is -$1.16.
What is Serina Therapeutics Inc (SER) EBITDA?
Serina Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -7.42 million.
Does Serina Therapeutics Inc (SER) pay dividends?
No. Serina Therapeutics Inc does not pay a dividend.
When is Serina Therapeutics Inc (SER) next earnings report?
Serina Therapeutics Inc is expected to release its next earnings report on September 30, 2026.
What is Serina Therapeutics Inc (SER) beta (volatility) score?
Serina Therapeutics Inc has a beta of 0.087, indicating lower volatility than the overall market.
